A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is application/pdf
.
Value of Tc99m (V) Dmsa Compared to Tc99m Mibi in Evaluation of Bone and Bone Marrow Lesions in Patients with Multiple Myeloma
2011
Research in Oncology
Multiple myeloma (MM) is primarily bone marrow neoplasm. Tc99m sestamibi (MIBI) is a potential imaging tracer in patients with multiple myeloma. Tc99m Pentavalent dimercaptosuccinic acid (V-DMSA) has an implication in imaging medullary carcinoma, head and neck tumors and soft tissue and bone tumors. Few reports evaluated imaging of multiple myeloma by Tc99m (V) DMSA and only one of them compared Tc99m (V) DMSA with Tc99m MIBI in assessment of chemotherapy effectiveness. objective: Is to compare
doi:10.21608/resoncol.2011.430
fatcat:aaf2rajsnjhrbijim7lsymyuji